Drug intelligence / Profile preview

Phenyldehydroalanine

Development stage: Unknown
Modality: Small Molecules

Overview

Phenyldehydroalanine (PDA) is an alpha,beta-unsaturated aromatic amino acid that was synthesized to serve as a sensitive spectroscopic probe. It is utilized in biochemical research to investigate the acylation process of the enzyme papain by specific substrates and inhibitors. The interaction of PDA, particularly when incorporated into peptides, with papain leads to significant red shifts in its absorption maxima, enabling the spectroscopic monitoring of acyl enzyme formation.

Other names: PDA

Targets

PEP (Pepsin)

Beyond the preview

Go deeper on Phenyldehydroalanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phenyldehydroalanine.

Explore the full profile